Hosted on MSN

RVPH: Open Label Extension Results & Key Opinion Leader Discussion

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) held a key opinion leader (KOL) event featuring two luminaries in the schizophrenia space to discuss brilaroxazine and the RECOVER open label ...
Seeking Alpha

Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

- Acoramidis demonstrated the earliest known time to separation in cardiovascular outcomes in the ATTRibute-CM study (3 months), with statistically significant risk reduction of 36% on All-Cause ...
Medscape

CIDP Benefits Persist in Efgartigimod Open-Label Extension

MONTREAL — An open-label extension study of subcutaneous efgartigimod PH20 to treat chronic inflammatory demyelinating polyneuropathy (CIDP) showed durability of functional improvements to week 24, ...
FierceBiotech

Alnylam Reports Six-Month Clinical Data from Patisiran Phase 2 Open-Label Extension (OLE) Study in Patients with Familial Amyloidotic Polyneuropathy (FAP)

CAMBRIDGE, Mass.--Alnylam Pharmaceuticals, Inc. (ALNY), a leading RNAi therapeutics company, announced today six-month clinical data from its ongoing Phase 2 open-label extension (OLE) study with ...
Nasdaq

Cytokinetics Presents New Data at CMR 2024 From FOREST-HCM, the Open Label Extension Clinical Trial of Aficamten

New Data Show Treatment with Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy Resulted in Favorable Structural Remodeling, Improvements in Cardiac Function and Stabilization of ...